Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S. Paller, Brad Shumel, Jamie Weisman et al.|Journal of the American Academy of Dermatology|2020Cited by 385
Dupilumab Improves Health-Related Quality of Life (HRQoL) and Reduces Symptom Burden in Patients with Eosinophilic Esophagitis (EoE): Results From Part A of a Randomized, Placebo-Controlled Three-Part Phase 3 StudyEvan S. Dellon, Siddhesh Kamat, Marc E. Rothenberg et al.|Journal of Allergy and Clinical Immunology|2021Cited by 13
Dupilumab Improves Clinical and Histologic Aspects of Disease in Adult and Adolescent Patients With Eosinophilic Esophagitis at Week 24: Results from Part B of the 3-Part LIBERTY EoE TREET StudyMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|Journal of Allergy and Clinical Immunology|2022Cited by 12
605 DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIALMirna Chehade, Arsalan Shabbir, Jennifer Maloney et al.|Gastroenterology|2023Cited by 2